DOCSLIB.ORG

2016 CM08 Arga 1.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2016 CM08 Arga 1.Pdf ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner have, or have had, within the past 12 months, which relates to the content of this educational activity and creates a conflict of interest. Dr. (INSERT NAME HERE) declares he/she has no conflict(s) of interest to disclose. OR Dr. (INSERT NAME HERE) declares affiliation with (INSERT AFFILIATION HERE) How Molecular Pathology Has Changed My Practice in Renal Neoplasia Pedram Argani, MD The Johns Hopkins Medical Institutions Baltimore, MD, USA [email protected] USCAP 2016 Renal Cell Carcinoma (RCC)-1997 • Clear cell • Papillary • Chromophobe • Collecting Duct – Medullary Renal Cell Carcinoma (RCC)-WHO 2016 • Clear cell RCC – Multilocular cystic renal neoplasm of low malignant potential • Papillary RCC • Hereditary leiomyomatosis RCC (HLRCC)-associated RCC • Chromophobe RCC • Collecting duct carcinoma • Renal medullary carcinoma • Mucinous tubular and spindle cell carcinoma • MiT family translocation RCC • Succinate dehydrogenase (SDH) deficient RCC • Tubulocystic RCC • Acquired cystic disease (ACD) associated RCC • Clear cell papillary RCC Two Common Problems in Renal Tumor Classification • RCC with Papillary Architecture and Clear Cells • Hard to Classify Eosinophilic Renal Neoplasms Case 1: 24 year old female with 3cm renal mass Renal Cell Carcinomas Which Often Have Papillary Architecture and Clear Cells • Clear cell RCC • Papillary RCC • Clear Cell Papillary RCC • Xp11 translocation RCC CLEAR CELL RCC CLEAR CELL RCC CLEAR CELL RCC: CA-IX PAPILLARY RCC PAPILLARY RCC: CK7 CLEAR CELL RCC PAPILLARY RCC Clear Cell Papillary RCC • 1-4% of RCC • Originally reported in ESRD but most sporadic • All typical cases have had benign outcome • Histology – Architecture: papillary, tubular – Cytology: clear sub nuclear cytoplasmlinear suprabasal low grade nuclei CLEAR CELL PAPILLARY RCC CLEAR CELL PAPILLARY RCC CK7 CA-IX CLEAR CELL PAPILLARY RCC MiT family Translocation RCC • Xp11 translocation RCC • t(6;11) RCC Xp11 translocation Renal Cell Carcinoma (RCC) • Definition – RCC with translocations involving Xp11 – Gene fusions involving TFE3 transcription factor • Diagnosis confirmed by – Nuclear labeling for TFE3 protein by IHC – TFE3 gene rearrangement by FISH • Often young patients – Median= 22 years – Comprise majority of pediatric RCC – Comprise 1-2% of adult RCC • Outcome similar to clear cell RCC – Stage and Age predict outcome Xp11 RCC CONFIRMED BY TFE3 BREAK-APART FISH Green WM et al. Am J Surg Pathol 2013;37:1150–1163 Cathepsin-K Immunoreactivity distinguishes Translocation RCC from other RCC Martignoni G et al. Mod Pathol 2009;22: 1016-1022 RCC with Papillary Architecture and Clear Cells CA-IX CK7 Cathepsin K Clear Cell RCC +++ - - Papillary RCC - +++ - Clear Cell Papillary RCC ++ +++ - Xp11 translocation RCC - - +/- Back to Our Case CK7- CA-IX- CATHEPSIN K- Diagnosis: Xp11 Translocation RCC with SFPQ-TFE3 Gene Fusion TFE3 BREAK-APART FISH SFPQ BREAK-APART FISH Johns Hopkins Cytogenetics Cristina Antonescu, MD Red, centromeric; green, telomeric Xp11 translocation RCC Fusion Age Translocation ASPL-TFE3 1-75 t(X;17)(p11.2;q25) PRCC-TFE3 2-69 t(X;1)(p11.2;q21) SFPQ-TFE3* 5-68 t(X;1)(p11.2;p34) NonO-TFE3* 29-51 inv(X)(p11.2;q12) CLTC-TFE3 14 t(X;17)(p11.2;q23) PARP14-TFE3 32 t(X;3)(p11.2;q23) DVL2-TFE3 73 t(X;17)(p11;p13) *typically show subnuclear vacuoles mimicking clear cell papillary RCC *typically Cathepsin K negative Am J Surg Pathol 2016, in press Hard to Classify Eosinophilic Renal Neoplasms Case 2: 54 year old female with 5cm renal mass Features Acceptable in Oncocytoma • Capsular invasion • Vascular invasion (rare) • Degenerative atypia Features that Exclude Oncocytoma • Well-Formed Papillae • Clear cells (non-focal) • Diffuse Cytokeratin 7 immunoreactivity • Wrinkly nuclei with well-preserved chromatin Renal Cell Carcinomas with Eosinophilic Cytoplasm • High Grade Clear Cell RCC • “Type 2” Papillary RCC • Eosinophilic Variant of Chromophobe RCC • Acquired Cystic Disease-Associated RCC (ACD-RCC) • Renal Medullary Carcinoma • VCL-ALK RCC • Collecting Duct Carcinoma • SHDB RCC • HLRCC-associated RCC • MiT family translocation RCC CLEAR CELL RCC CLEAR CELL RCC “type“Type II Papillary II Papillary RCC” RCC” “Type II Papillary RCC” • TCGA Study (NEJM 2015 Nov4 Epub) – At least 3 different entities genetically – 5% are actually MiT family Translocation RCC! • WHO 2016: “ may not in fact constitute a single well defined entity… but remains a useful morphologic descriptor ” Acquired Cystic Disease- Associated RCC (ACD-RCC) • Most common RCC in End Stage Renal Disease (36%), particularly in ACD (46%) • 50% multifocal, 20% bilateral Tickoo S et al. Am J Surg Pathol 2006;30: 141-153 ACD-RCC: Key Features • Cribriform/Sievelike Architecture – Intercellular and Intracellular Lumina • Eosinophilic Cytoplasm, Prominent Nucleolus • Intratumoral Oxalate Crystals ACD-RCC ACD-RCC Succinate Dehydrogenase Deficient RCC (SDH RCC) • Germline succinate dehydrogenase B mutations • PGL4 Syndrome – Pheochromocytoma – Paraganglioma – Type II GIST • Pediatric, Carney syndrome – Renal Neoplasms (14% lifetime risk) Barletta JA, Hornick JL. Adv Anat Pathol. 2012;19:193-203 SDHB RCC • Less than 0.6% of RCC • Typically young adults, 26% bilateral • Indolent course in most cases – Rare cases with aggressive histologic features metastasize – Can metastasize late (16, 30 years after resection) Gill AJ Am J Surg Pathol 2014;38: 1588-1602 Williamson SR Mod Pathol 2015;28: 80-94 SDHB RCC • Compact nests of eosinophilic cells • Vacuolated cytoplasm • Pale eosinophilic cytoplasmic inclusions – Giant mitochondria • Loss of SDHB protein by IHC SDHB RCC VACUOLES SDHB RCC INCLUSIONS SDHB IHC Hereditary Leiomyomatosis Renal Cell Carcinoma (HLRCC)- associated RCC Hereditary Leiomyomatosis Renal Cell Carcinoma (HLRCC) Syndrome • Autosomal Dominant • Germline mutations in Fumarate Hydratase gene (1q42) • Multiple Cutaneous and Uterine Leiomyomas – 50% of women have hysterectomy before age 30 • RCC – 1/3 of patients – Solitary – Aggressive HLRCC-associated RCC HLRCC-associated RCC HLRCC-associated RCC: IHC Markers • Aberrant succination of proteins S-(2-succinyl) cysteine (2 SC) IHC – Bardella C et al. J Pathol 2011;225: 4-11 – Chen YB et al. Am J Surg Pathol 2014;38: 627-637 • Loss of Fumarate Hydratase by IHC – Trypkov K et al. Am J Surg Pathol 2016, in press Renal Cell Carcinomas Associated with Sickle Cell Trait • Renal Medullary Carcinoma – Often rhabdoid morphology – Loss of INI1 expression – Poor prognosis • VCL-ALK RCC – Vacuolated Cytoplasm – INI1 intact – Prognosis unclear Renal Medullary Carcinoma VCL-ALK RCC Back to Our Case Additional Sections FUMARATE HYDRATASE Diagnosis: HLRCC-Associated RCC Hard to Classify Eosinophilic Renal Neoplasms • r/o Oncocytoma • Consider high grade clear cell RCC • Beware of type II PRCC • Clues – Young age: MiT family Translocation RCC – ESRD: ACD-RCC – Sickle Cell Trait: RMC, VCL-ALK RCC – Vacuoles, Inclusions: SDHB RCC – Prominent Nucleoli: HLRCC-associated RCC Arthur Purdy Stout Society March 13, 2016 How has molecular pathology changed my diagnostic surgical pathology practice? Renal Neoplasia Pedram Argani MD The Johns Hopkins Medical Institutions [email protected] I. Renal Cell Carcinomas (RCCs) with Clear Cells and Papillary Features Clear Cell RCC Clear cell RCC represents the most common RCC subtype, comprising approximately 60% of all renal tumors. The typical architecture is solid or acinar, with clear cells separated by hypervascular thin fibrous septa. The neoplastic cells of low nucleolar grade clear cell RCC (ISUP grade 1-2) typically have water-clear, virtually agranular cytoplasm. However, high nucleolar grade clear cell RCC typically has densely granular eosinophilic cytoplasm. Rarely, true cases of low grade clear cell RCC have well-developed papillae. In other low grade tumors, small papillae lined by clear cells protrude into cystic spaces. More commonly, high grade clear cell RCC with necrosis demonstrate pseudopapillae resulting from fragmentation of the acinar architecture. Additional sections of such tumors often show diagnostic lower grade acinar areas with clear cytoplasm. Clear cell RCC typically demonstrates strong immunoreactivity for cytokeratin Cam5.2, vimentin, CD10, EMA, RCC marker as well as PAX8 and/or PAX2. Additionally, diffuse membranous staining for CA-IX is present, reflecting inactivation of the von Hippel-Landau (VHL) gene and constitutive activation of the hypoxia-inducible-factor (HIF) pathway. Notably, clear cell RCCs are typically negative for both cytokeratin 7 (CK7) and α-methylacyl-CoA racemase (AMACR), though both may be focally positive, especially in higher grade tumors. CK7 may also label cystic areas. Cathepsin K is consistently negative. In summary, the most helpful morphologic clue for a clear cell RCC is hypervascular septa intimately associated with the neoplastic cells with transparent clear cytoplasm. Features further supporting the diagnosis are diffuse, strong, complete membranous CA-IX labeling and absence of CK7 labeling by IHC, as well as chromosome 3p loss by genetics. Papillary RCC Papillary RCC comprises 11-20% of renal tumors. In contrast to other RCC subtypes, papillary RCC is the more often multifocal (up to 45% of cases) and these typically are of independent origin. The prognosis is more favorable for papillary RCC than for clear cell RCC. Histologically,
Load more

Recommended publications
  • Molecular Cytogenetic Analysis for TFE3 Rearrangement In
    Modern Pathology (2014) 27, 113–127 & 2014 USCAP, Inc. All rights reserved 0893-3952/14 $32.00 113 Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases Jennelle C Hodge, Kathryn E Pearce, Xiaoke Wang, Anne E Wiktor, Andre M Oliveira and Patricia T Greipp Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA Renal cell carcinoma with TFE3 rearrangement at Xp11.2 is a distinct subtype manifesting an indolent clinical course in children, with recent reports suggesting a more aggressive entity in adults. This subtype is morphologically heterogeneous and can be misclassified as clear cell or papillary renal cell carcinoma. TFE3 is also rearranged in alveolar soft part sarcoma. To aid in diagnosis, a break-apart strategy fluorescence in situ hybridization (FISH) probe set specific for TFE3 rearrangement and a reflex dual-color, single-fusion strategy probe set involving the most common TFE3 partner gene, ASPSCR1, were validated on formalin-fixed, paraffin- embedded tissues from nine alveolar soft part sarcoma, two suspected Xp11.2 renal cell carcinoma, and nine tumors in the differential diagnosis. The impact of tissue cut artifact was reduced through inclusion of a chromosome X centromere control probe. Analysis of the UOK-109 renal carcinoma cell line confirmed the break-apart TFE3 probe set can distinguish the subtle TFE3/NONO fusion-associated inversion of chromosome X. Subsequent extensive clinical experience was gained through analysis of 75 cases with an indication of Xp11.2 renal cell carcinoma (n ¼ 54), alveolar soft part sarcoma (n ¼ 13), perivascular epithelioid cell neoplasms (n ¼ 2), chordoma (n ¼ 1), or unspecified (n ¼ 5).
    [Show full text]
  • Renal Cell Carcinoma – Detection of PRCC-TFE3 and Alpha-TFEB Gene Fusions Using RT-PCR on Tissues (Odes 60153 and 60154) Notice of Assessment
    Renal Cell Carcinoma – Detection of PRCC-TFE3 and Alpha-TFEB Gene Fusions Using RT-PCR on Tissues (odes 60153 and 60154) Notice of Assessment June 2013 DISCLAIMER: This document was originally drafted in French by the Institut national d'excellence en santé et en services sociaux (INESSS), and that version can be consulted at http://www.inesss.qc.ca/fileadmin/doc/INESSS/Analyse_biomedicale/Juin_2013/INESSS_Analyse_15.pdf http://www.inesss.qc.ca/fileadmin/doc/INESSS/Analyse_biomedicale/Juin_2013/INESSS_Analyse_16.pdf It was translated into English by the Canadian Agency for Drugs and Technologies in Health (CADTH) with INESSS’s permission. INESSS assumes no responsibility with regard to the quality or accuracy of the translation. While CADTH has taken care in the translation of the document to ensure it accurately represents the content of the original document, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the information in this document, the original document, or in any of the source documentation. 1 GENERAL INFORMATION 1.1 Requestor: Centre hospitalier universitaire de Québec (CHUQ). 1.2 Application Submitted: August 1, 2012. 1.3 Notice Issued: April 12, 2013. Note: This notice is based on the scientific and commercial information (submitted by the requestor[s]) and on a complementary review of the literature according to the data available at the time that this test was assessed by INESSS. 2 TECHNOLOGY, COMPANY, AND LICENCE(S) 2.1 Name of the Technology Reverse transcription of messenger RNA and amplification (RT-PCR).
    [Show full text]
  • A Novel Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of EWSR1-TFE3 Fusion
    Virchows Archiv (2019) 474:389–393 https://doi.org/10.1007/s00428-018-2509-8 BRIEF REPORT A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion Hironori Fukuda1 & Ikuma Kato2 & Mitsuko Furuya2 & Reiko Tanaka3 & Toshio Takagi1 & Tsunenori Kondo1,4 & Yoji Nagashima5 Received: 28 August 2018 /Revised: 13 November 2018 /Accepted: 10 December 2018 /Published online: 14 December 2018 # Springer-Verlag GmbH Germany, part of Springer Nature 2018 Abstract The renal cell carcinomas associated with Xp11 translocations (Xp11 translocation RCCs) harbor gene fusions involving TFE3,a member of the microphthalmia-associated transcription factor (MiTF) family. In the present study, we identified a novel partner of TFE3, Ewing sarcoma breakpoint region 1 (EWSR1), in an Xp11 translocation RCC. A 57-year-old Japanese woman without special disease history was referred to us for treatment of an RCC. The resected tumor displayed an alveolar growth pattern with high-grade nuclei. The tumor was diffusely positive for TFE3 and cathepsin K. Anchored multiplex PCR revealed a novel fusion, EWSR1-TFE3. Fluorescent in situ hybridization analysis demonstrated the rearrangements of EWSR1 and TFE3. RT-PCR analysis confirmed the chimeric transcript. No neoplasm with EWSR1-TFE3 has been reported so far, in any organ. The results will expand the genomic spectrums of Xp11 translocation RCCs and contribute to better understanding of the roles of the MiTF family in the oncogenic process. Keywords
    [Show full text]
  • Metastatic Tfe3-Overexpressing Renal Cell Carcinoma
    ISSN: 2378-3419 Ribeiro et al. Int J Cancer Clin Res 2021, 8:148 DOI: 10.23937/2378-3419/1410148 Volume 8 | Issue 2 International Journal of Open Access Cancer and Clinical Research CASe RePoRt Metastatic Tfe3-Overexpressing Renal Cell Carcinoma: Case Report and Literature Review Paulo Victor Zattar Ribeiro1, Leonora Zozula Blind Pope2, Beatriz Granelli1, Milena Luisa Schulze1*, Andréa Rodrigues Cardovil Pires3 and Mateus da Costa Hummelgen1 1University of Joinville’s Region, UNIVILLE, Brazil 2Dona Helena Hospital, Blumenau Street, Brazil Check for 3Diagnostic Medicine Fonte, São Sebastião, Brazil updates *Corresponding author: Milena Luisa Schulze, Department of Medicine, University of Joinville’s Region, UNIVILLE, Paulo Malschitzki Street, 10 - Zona Industrial Norte, 89249-710 Joinville – SC, Brazil Abstract Introduction Background: Renal cell carcinoma (RCC) associated with Renal cell carcinoma (RCC) associated with Xp11.2 Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC) is a translocation/TFE3 gene fusion (Xp11.2 RCC) is a rare rare subtype of RCC which is delineated as a distinct entity subtype of RCC which is delineated as a distinct enti- in the 2004 World Health Organization renal tumor classi- fication. ty in the 2004 World Health Organization renal tumor classification. Its morphology and clinical manifesta- Objective: To highlight a rare case, with few publications tions often overlap with those of conventional RCCs [1]. on the topic, in addition to providing scientific explanations about it. Children are more affected by this subtype than adults, accounts for 20-40% of pediatric RCC and 1-1.6% of RCC Method: This is a case report of a 58-year-old white male with the diagnosis of renal clear cell carcinoma (RCC).
    [Show full text]
  • Atlas Journal
    Atlas of Genetics and Cytogenetics in Oncology and Haematology Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Portal Teaching X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Atlas Journal Atlas Journal versus Atlas Database: the accumulation of the issues of the Journal constitutes the body of the Database/Text-Book. TABLE OF CONTENTS Volume 3, Number 2, Apr-Jun 1999 Previous Issue / Next Issue Genes NONO (Xq12). Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (2): 133-136. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/NONOID168.html PRCC (papillary renal cell carcinoma) (1q21.2). François Desangles, Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (2): 137-140. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/PRCCID69.html PSF (PTB-associated splicing factor) (1p34). Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (2): 141-144. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/PSFID167.html PTCH1 (9q22.3) - updated. Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (2): 145-153. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/PTCH100.html TFE3 (transcription factor E3) (Xp11.2). Jean-Loup Huret, François Desangles. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (2): 154-160. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/TFE3ID86.html HRAS (Harvey rat sarcoma viral oncogene homolog) (11p15.5). Franz Watzinger, Thomas Lion. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (2): 161-172. [Full Text] [PDF] Atlas Genet Cytogenet Oncol Haematol 1999; 2 I URL : http://AtlasGeneticsOncology.org/Genes/HRASID108.html K-RAS (Kirsten rat sarcoma 2 viral oncogene homolog) (12p12).
    [Show full text]
  • Proteomic Characterization of Transcription and Splicing Factors Associated with a Metastatic Phenotype in Colorectal Cancer
    Proteomic characterization of transcription and splicing factors associated with a metastatic phenotype in colorectal cancer Sofía Torres1+, Irene García-Palmero1+, Consuelo Marín-Vicente1,2, Rubén A. Bartolomé1, Eva Calviño1, María Jesús Fernández-Aceñero3 and J. Ignacio Casal1* +. Equal authorship 1. Functional proteomics. Centro de Investigaciones Biológicas (CIB-CSIC). Ramiro de Maeztu 9. Madrid. Spain. 2. Proteomic facilities. CIB-CSIC. Madrid. Spain 3. Department of Pathology. Hospital Clínico. Madrid. Spain Running title: Transcription factors in metastatic colorectal cancer Keywords: SRSF3, transcription factors, splicing factors, metastasis, colorectal cancer *. Corresponding author J. Ignacio Casal Department of Cellular and Molecular Medicine Centro de Investigaciones Biológicas (CIB-CSIC) Ramiro de Maeztu, 9 28040 Madrid, Spain Phone: +34 918373112 Fax: +34 91 5360432 Email: [email protected] 1 ABSTRACT We investigated new transcription and splicing factors associated with the metastatic phenotype in colorectal cancer. A concatenated tandem array of consensus transcription factors (TFs)-response elements was used to pull down nuclear extracts in two different pairs of colorectal cancer cells, KM12SM/KM12C and SW620/480, genetically-related but differing in metastatic ability. Proteins were analyzed by label-free LC-MS and quantified with MaxLFQ. We found 240 proteins showing a significant dysregulation in highly- metastatic KM12SM cells relative to non-metastatic KM12C cells and 257 proteins in metastatic SW620 versus SW480. In both cell lines there were similar alterations in genuine TFs and components of the splicing machinery like UPF1, TCF7L2/TCF-4, YBX1 or SRSF3. However, a significant number of alterations were cell-line specific. Functional silencing of MAFG, TFE3, TCF7L2/TCF-4 and SRSF3 in KM12 cells caused alterations in adhesion, survival, proliferation, migration and liver homing, supporting their role in metastasis.
    [Show full text]
  • Amplification and Overexpression of E2F3 in Human Bladder Cancer
    Oncogene (2004) 23, 1627–1630 & 2004 Nature Publishing Group All rights reserved 0950-9232/04 $25.00 www.nature.com/onc SHORT REPORTS Amplification and overexpression of E2F3 in human bladder cancer Andrew Feber1, Jeremy Clark1, Graham Goodwin1, Andrew R Dodson2, Paul H Smith2, Anne Fletcher1, Sandra Edwards1, Penny Flohr1, Alison Falconer3, Toby Roe1, Gyula Kovacs4, Nening Dennis1, Cyril Fisher5, Richard Wooster6, Robert Huddart3, Christopher S Foster2 and Colin S Cooper*,1 1Section of Molecular Carcinogenesis and Male Urological Cancer Research, Centre, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK; 2Department of Pathology and Molecular Genetics, University of Liverpool, Duncan Building, Daulby Street, Liverpool L69 3GA, UK; 3Royal Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK; 4Ruprecht-Karls-Universitat, Heidelberg Klinikum, Molekular Onkologie, Im Neuenheimer Feld 365, Heidelberg 69120, Germany; 5Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK; 6Sanger Centre, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK We demonstrate that, in human bladder cancer, amplifi- H-RAS and FGFR3 (Cappellen et al., 1999; Knowles, cation of the E2F3 gene, located at 6p22, is associated 2001). Comparative genomic hybridization (CGH) and with overexpression of its encoded mRNA transcripts and loss of heterozygosity studies have also identified many high levels of expression of E2F3 protein. Immunohisto- consistent regions of chromosomal gain and loss that chemical analyses of E2F3 protein levels have established may be sites of additional oncogenes and tumour- that around one-third (33/101) of primary transitional cell suppressor genes in bladder cancer (Knowles, 2001). In carcinomas of the bladder overexpress nuclear E2F3 these studies, gains and amplification at 6p22 have been protein, with the proportion of tumours containing over- frequently found in human bladder cancer (Hovey et al., expressed nuclear E2F3 increasing with tumour stage and 1998; Koo et al., 1999; Terracciano et al., 1999; Simon grade.
    [Show full text]
  • TFE3 Regulates Renal Adenocarcinoma Cell Proliferation Via Activation of the Mtor Pathway
    MOLECULAR MEDICINE REPORTS 16: 2721-2725, 2017 TFE3 regulates renal adenocarcinoma cell proliferation via activation of the mTOR pathway YUAN FANG1,2, WEI BAO2, QIU RAO2, XUAN WANG2, QIUYUAN XIA2, QIN SHEN2, XIAOJUN ZHOU2 and BING YAO1 1Reproductive Medical Center and 2Department of Pathology, Jinling Hospital, Clinical Medical School of Southern Medical University, Nanjing, Jiangsu 210002, P.R. China Received August 17, 2016; Accepted May 15, 2017 DOI: 10.3892/mmr.2017.6930 Abstract. The present study aimed to investigate the role of Introduction transcription factor E3 (TFE3) in the regulation of proliferation in renal adenocarcinoma cells. The LV-TFE3 overexpression Xp11.2 translocation renal cell carcinomas (RCCs) are the most (OE) lentivirus and negative control CON195 (NC) lentivirus common subtype of pediatric RCCs, in addition to affecting were transfected into the ACHN cell line. Protein expression ~1.5% of adults (1,2). Xp11.2 translocation RCCs were first of FLAG-tag TFE3 was determined using western blot anal- identified to be a novel, genetically distinct disease in the ysis. Differences in cell proliferation, plate clone formation 2010 World Health Organization renal tumor classification (3). and cell cycle distribution between OE and NC groups were Xp11.2 translocation RCCs are characterized by chromosomal compared using MTT, plate colony formation and flow cytom- translocations involving the Xp11.2 breakpoint, resulting etry assays, respectively. The levels of mammalian target of in transcription factor E3 (TFE3) gene fusion. TFE3 fusion rapamycin (mTOR) and phosphorylated ribosomal protein S6 with other regulatory elements and TFE3 overexpression is a (p-rpS6) were analyzed by western blotting.
    [Show full text]
  • Smad Regulation in TGF-(Beta) Signal Transduction
    COMMENTARY 4359 Smad regulation in TGF-β signal transduction Aristidis Moustakas, Serhiy Souchelnytskyi and Carl-Henrik Heldin Ludwig Institute for Cancer Research, Box 595, SE-751 24 Uppsala, Sweden Corresponding author (e-mail: [email protected]) Journal of Cell Science 114, 4359-4369 (2001) © The Company of Biologists Ltd Summary Smad proteins transduce signals from transforming growth promote degradation of transcriptional repressors, thus factor-β (TGF-β) superfamily ligands that regulate cell facilitating target gene regulation by TGF-β. Smads proliferation, differentiation and death through activation themselves can also become ubiquitinated and are of receptor serine/threonine kinases. Phosphorylation of degraded by proteasomes. Finally, the inhibitory Smads (I- receptor-activated Smads (R-Smads) leads to formation of Smads) block phosphorylation of R-Smads by the receptors complexes with the common mediator Smad (Co-Smad), and promote ubiquitination and degradation of receptor which are imported to the nucleus. Nuclear Smad complexes, thus inhibiting signalling. oligomers bind to DNA and associate with transcription factors to regulate expression of target genes. Alternatively, Key words: Phosphorylation, Signal transduction, Smad, nuclear R-Smads associate with ubiquitin ligases and Transforming growth factor-β, Ubiquitination Introduction chromosome 15q21-22, and MADH5, MADH1 and MADH8 Members of the transforming growth factor-β (TGF-β) family to chromosomes 15q31, 4 and 13, respectively (Gene control growth, differentiation
    [Show full text]
  • Fusion of the Genes PHF1 and TFE3 in Malignant Chondroid Syringoma
    CANCER GENOMICS & PROTEOMICS 16 : 345-351 (2019) doi:10.21873/cgp.20139 Fusion of the Genes PHF1 and TFE3 in Malignant Chondroid Syringoma IOANNIS PANAGOPOULOS 1, LUDMILA GORUNOVA 1, MARIUS LUND-IVERSEN 2, ASSIA BASSAROVA 2 and SVERRE HEIM 1,3 1Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; 2Department of Pathology, Oslo University Hospital, Oslo, Norway; 3Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway Abstract. Background/Aim: Malignant chondroid syringoma men and show predilection for the trunk and extremities (1- is a rare tumor of unknown pathogenesis. Materials and 3). The clinical course is unpredictable (4). Half of the Methods: Genetic analyses were performed on a malignant reported cases had local recurrences whereas nodal and distant chondroid syringoma. Results: G-banding analysis of short- metastases were observed in 39% and 36% of the cases, term cultured tumor cells yielded the karyotype respectively. The most common sites for distant metastases are 46,Y,t(X;6)(p11;p21)[15]/46,XY[2]. RNA sequencing detected the lungs, bone, and brain (4). Malignant chondroid syringoma an in-frame fusion of PHF1 from 6p21 with TFE3 from Xp11, is composed of both epithelial and mesenchymal tissue. The verified by RT-PCR and Sanger sequencing. Genomic PCR epithelial component consists of neoplastic cells with showed that the PHF1-TFE3 junction was identical to the hyperchromatic nuclei and abundant mitotic figures, with fusion found by RNA sequencing and RT-PCR. Conclusion: occasional areas of necrosis. The mesenchymal component Malignant chondroid syringoma is genetically related to may show myxoid, chondroid, osteoid, adipose or fibrous tumors with PHF1 rearrangements such as low-grade features enclosing clusters of epithelial cells (1-3).
    [Show full text]
  • PRCC, the Commonest TFE3 Fusion Partner in Papillary Renal Carcinoma Is Associated with Pre-Mrna Splicing Factors
    Oncogene (2001) 20, 178 ± 187 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors YM Skalsky*,1, PM Ajuh2, C Parker1, AI Lamond2, G Goodwin1 and CS Cooper1 1Institute of Cancer Research, Molecular Carcinogenesis Section, The Haddow Laboratories, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK; 2Department of Biochemistry, The University of Dundee, MSI/WTB Complex, Dow Street, Dundee, DD1 5EH, UK In papillary renal cell carcinomas the TFE3 transcription shown to contain the PRCC ± TFE3, PSF ± TFE3 or factor becomes fused to the PSF and NonO pre-mRNA NonO ± TFE3 fusions, but not always reciprocal splicing factors and most commonly to a protein of fusions, they are the protein structures that believed unknown function designated PRCC. In this study we to be involved in carcinogenesis. have examined the ability of the resulting PRCC ± TFE3 TFE3 is a transcription factor that was originally and NonO ± TFE3 fusions to activate transcription from identi®ed by its ability to bind the mE3 site in the IgH the plasminogen activator inhibitor-1 (PAI-1) promoter. enhancer (Beckmann et al., 1990). The 576aa protein The results show that only fusion to PRCC enhanced contains a basic helix ± loop ± helix domain involved in transcriptional activation, indicating that the ability to DNA binding and two transcriptional activation enhance the level of transcription from endogenous TFE3 domains: an N-terminal acidic activation domain and promoters is not a consistent feature of TFE3 fusions.
    [Show full text]
  • MITF: Master Regulator of Melanocyte Development and Melanoma Oncogene
    Review TRENDS in Molecular Medicine Vol.12 No.9 MITF: master regulator of melanocyte development and melanoma oncogene Carmit Levy, Mehdi Khaled and David E. Fisher Melanoma Program and Department of Pediatric Hematology and Oncology, Dana-Farber Cancer Institute, Children’s Hospital Boston, 44 Binney Street, Boston, MA 02115, USA Microphthalmia-associated transcription factor (MITF) between MITF and TFE3 in the development of the acts as a master regulator of melanocyte development, osteoclast lineage [8]. From these analyses, it seems that function and survival by modulating various differentia- MITF is the only MiT family member that is functionally tion and cell-cycle progression genes. It has been essential for normal melanocytic development. demonstrated that MITF is an amplified oncogene in a MITF is thought to mediate significant differentiation fraction of human melanomas and that it also has an effects of the a-melanocyte-stimulating hormone (a-MSH) oncogenic role in human clear cell sarcoma. However, [9,10] by transcriptionally regulating enzymes that are MITF also modulates the state of melanocyte differentia- essential for melanin production in differentiated melano- tion. Several closely related transcription factors also cytes [11]. Although these data implicate MITF in both the function as translocated oncogenes in various human survival and differentiation of melanocytes, little is known malignancies. These data place MITF between instruct- about the biochemical regulatory pathways that control ing melanocytes towards terminal differentiation and/or MITF in its different roles. pigmentation and, alternatively, promoting malignant behavior. In this review, we survey the roles of MITF as a Transcriptional and post-translational MITF regulation master lineage regulator in melanocyte development The MITF gene has a multi-promoter organization in and its emerging activities in malignancy.
    [Show full text]